Survival rate and perioperative data of patients who have undergone hemipelvectomy: a retrospective case series

Couto, Alfredo Guilherme Haack; Araújo, Bruno Espírito Santo de; Vasconcelos, Roberto André Torres de; Renni, Marcos José; Fonseca, Clóvis Orlando da; Cavalcanti, Ismar Lima

doi:10.1186/s12957-016-1001-7

Cited by 24 publications

(18 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The 5-year overall survival and LRFS rates for the 21 patients in the study cohort were 67% and 76%, respectively, comparable with the rates previously reported for internal and external hemipelvectomy. 23 In the literature, the 5-year overall survival of patients with periacetabular tumors has been reported between 62.4% and 70%. 24,25 Hu et al 17 reported a 5-year overall survival rate of 77.8% in 27 patients with periacetabular tumors who were managed by resection hip arthroplasty.…”

Section: Oncological Outcomesmentioning

confidence: 99%

Reconstruction after periacetabular tumor resection with Lumic® endoprosthesis: What are the midterm results?

Erol

Sofulu

Şirin

et al. 2020

Journal of Surgical Oncology

View full text Add to dashboard Cite

IntroductionThis study aimed to analyze the midterm outcomes of LUMiC® endoprosthetic reconstruction following periacetabular resection of primary bone sarcomas and carcinoma metastases.Patients and MethodsWe retrospectively reviewed the charts of 21 patients (11 male [52.3%], 10 female [47.6%]; mean age 47 ± 16 years) for whom a LUMiC® endoprosthesis (Implantcast) was used to reconstruct a periacetabular defect after internal hemipelvectomy. The tumor was pathologically diagnosed as Ewing's sarcoma in six (28.5%), chondrosarcoma in 10 (47.6%), and bone metastasis from carcinoma in five (23.8%) patients.ResultsThe median follow‐up of patients was 57.8 months (95% confidence interval: 51.9–63.7). The implant survival rate at 1, 2, and 5 years were 95.2%, 85.7%, and 80.9%, respectively. The overall complication rate was 33.3% (n = 7). Four (19%) complications resulted in reconstruction failure. Total reoperation rate was 28.5% (n = 6). The complications were soft tissue failure/dislocation in two patients, aseptic loosening in one, infection in two, and local recurrence in two. At the time of study, seven patients were alive with no evidence of disease, seven were alive with disease, and seven died of disease. The 5‐year overall survival rate and local recurrence‐free survival rates were 67% and 76%, respectively. The median Musculoskeletal Tumor Society score at final follow‐up was 70% (range: 50%–86.6%).ConclusionWe conclude that LUMiC® endoprosthesis provides good functional outcomes and a durable reconstruct. Even though this reconstruction method presents some complications, it provides a stable pelvis in the management of periacetabular malignant tumors.

show abstract

Section: Oncological Outcomesmentioning

confidence: 99%

Reconstruction after periacetabular tumor resection with Lumic® endoprosthesis: What are the midterm results?

Erol

Sofulu

Şirin

et al. 2020

Journal of Surgical Oncology

View full text Add to dashboard Cite

show abstract

“…Detail pain assessment was not a part of the protocol, with the study primarily looking at survival rates after hemipelvectomy. 15 Our study shows a 30% incidence of CPSP in patients undergoing resection surgeries for pelvic tumours. We also report a high incidence of numbness in and around the area of surgical incision (50%) which tends to linger for a long time.…”

Section: Discussionmentioning

confidence: 55%

“Prevalence of chronic pain following resection of pelvic bone tumours: A single centre prospective observational survey”

Bakshi

Rana

Gulia

et al. 2021

British Journal of Pain

View full text Add to dashboard Cite

Background Hemipelvectomy is a major surgery most often performed for pelvic malignancy. These complex surgeries often involve dissection around major neurovascular bundle and resection of tumour being bone along with involved tissues. This may result in short and long term morbidities. There is very little literature about incidence of chronic pain after pelvic resections. We conducted a prospective study at a tertiary cancer hospital to assess the prevalence of chronic pain post hemipelvectomy. Method This is a single centre prospective observational study conducted over 30 months. Pain scores were recorded using Brief pain inventory (BPI) and pain detect questionnaire. The quality of life was assessed using musculoskeletal tumour society (MSTS) score. Intra-operative details like extent of surgical resection, nerves spared, details of intra-operative and post-operative analgesia were retrieved from the patient files. Data were analysed using SPSS 21 version. Results Neuropathic pain post hemipelvectomy was uncommon. The prevalence of mild to moderate somatic pain was around 30%. Functional limitation was minimal as assessed by BPI and MSTS score. A high incidence of numbness was seen to persist in and around the area of surgical incision (50%). Conclusion This is first study to report the incidence of chronic pain post hemipelvectomy done for pelvic tumour resections. Despite the extensive nature of resection involved, there is a low prevalence of neuropathic pain in this population. However, incidence of persistent somatic pain is high and there is a need for further studies for evaluating the causality

show abstract

“…Therefore, it is also very important to give appropriate adjuvant chemotherapy and neoadjuvant chemotherapy according to different pathological types [ 15 ]. In addition, the study of Alfredo Guilherme Haack Couto et al found that the survival rate of patients with bone tumors was significantly higher than those of soft tissue sarcomas, and they found that almost all patients with soft tissue tumors had more advanced tumor stages (stage III or IV), which may be the reason for the decreased survival rate [ 25 ].…”

Section: Discussionmentioning

confidence: 99%

New adjustable modular hemipelvic prosthesis replacement with 3D-print osteotomy guide plate used in periacetabular malignant tumors: a retrospective case series

Liu

Peng

et al. 2022

J Orthop Surg Res

View full text Add to dashboard Cite

Background Periacetabular malignant tumor seriously endangers the life and health of patients. Hemipelvic replacement provides a good method for patients who want complete resection of the tumor while retaining or restoring the function of the affected limb. Objective To investigate the performance and clinical application of the new adjustable modular hemipelvic prosthesis and to compare the effects of three kinds of hemipelvic prosthesis. Methods In this study, 23 patients, with an average age of 44.6 years (21–75 years), were collected, who received hemipelvic replacement with new adjustable, modular, and screw-rod system hemipelvic prosthesis. Preoperative preparation was conducted on them, and operative complications were recorded. Postoperative functional follow-up was performed regularly. Results The average operation time was 319 min (170–480 min), and the average blood loss was 2813 ml (1000 mL-8000 ml). The incidence of complications was 47.8%, and type A (wound-related complications) had the highest incidence (34.8%). Postoperative dislocation occurred in 3 cases (13.0%), and no dislocation occurred in the new adjustable modular hemipelvic prosthesis group. The average MSTS score of the patients was 18.6 (10–23), and the average Harris score was 73.7 (53–87). Conclusions The new adjustable modular hemipelvic prosthesis has the feasibility of reconstruction and good functional outcome, making it ideal for periacetabular tumors. Furthermore, preoperative tumor-feeding artery embolization and abdominal aortic balloon implantation may be an effective choice to reduce intraoperative blood loss and facilitate the operation of tumor resection.

show abstract

Survival rate and perioperative data of patients who have undergone hemipelvectomy: a retrospective case series

Cited by 24 publications

References 23 publications

Reconstruction after periacetabular tumor resection with Lumic® endoprosthesis: What are the midterm results?

Reconstruction after periacetabular tumor resection with Lumic® endoprosthesis: What are the midterm results?

“Prevalence of chronic pain following resection of pelvic bone tumours: A single centre prospective observational survey”

New adjustable modular hemipelvic prosthesis replacement with 3D-print osteotomy guide plate used in periacetabular malignant tumors: a retrospective case series

Contact Info

Product

Resources

About